for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dr Reddy's Laboratories Ltd (ADR)

RDY.N

Latest Trade

63.09USD

Change

-0.75(-1.17%)

Volume

32,777

Today's Range

63.05

 - 

64.10

52 Week Range

57.55

 - 

75.42

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Dr. Reddy's Laboratories Enters Into Definitive Agreement With Citius Pharmaceuticals To Sell Its Rights To Anti-Cancer Agent E7777 (Denileukin Diftitox)

Sept 4 (Reuters) - Dr Reddy's Laboratories Ltd <REDY.NS>::PRESS RELEASE - DR. REDDY’S LABORATORIES ENTERS INTO DEFINITIVE AGREEMENT WITH CITIUS PHARMACEUTICALS, INC. TO SELL ITS RIGHTS TO ANTI-CANCER AGENT E7777 (DENILEUKIN DIFTITOX).DR REDDY'S LABORATORIES- CO WILL RECEIVE $40 MILLION ON CLOSING OF TRANSACTION.DR REDDY'S LABORATORIES - CO WILL ALSO RECEIVE APPROVAL PAYMENT OF UP TO $40 MILLION RELATED TO CTCL INDICATION APPROVAL AND UP TO $70 MILLION FOR ADDITIONAL INDICATION APPROVALS.

Panacea Biotec To Make Up To 25 Mln Doses Of Sputnik V Vaccine

Aug 5 (Reuters) - Panacea Biotec Ltd <PNCA.NS>::ENTERED LICENSING AND MANUFACTURING AGREEMENT WITH HUMAN VACCINE LIMITED LIABILITY CO ON AUG 3.AGREEMENT IS FOR MANUFACTURE OF UPTO 25 MILLION DOSES OF SPUTNIK V VACCINE.AGREEMENT WITH A UNIT OF RUSSIAN DIRECT INVESTMENT FUND AND DR. REDDY'S JV.

Dr.Reddy's Labs June-Quarter Consol Profit Falls

July 27 (Reuters) - Dr Reddy's Laboratories Ltd <REDY.NS>::JUNE-QUARTER CONSOL PROFIT 5.71 BILLION RUPEES VERSUS 5.79 BILLION RUPEES YEAR AGO.JUNE-QUARTER CONSOL REVENUE 49.19 BILLION RUPEES VERSUS 44.18 BILLION RUPEES YEAR AGO.ON JULY 6, GOT SUBPOENA FROM U.S. SECURITIES AND EXCHANGE COMMISSION.GOT ANONYMOUS COMPLAINT ALLEGING HEALTHCARE PROFESSIONALS IN UKRAINE, POTENTIALLY OTHER COUNTRIES PAID IMPROPERLY BY CO.Further company coverage: <REDY.NS>. ((Reuters.Briefs@thomsonreuters.com;)).

Dr Reddy's Says Subject Expert Committee Deliberated On Co's Submission For Marketing Authorisation Of Sputnik Light In India

July 2 (Reuters) - Dr Reddy's Laboratories Ltd <REDY.NS>::DR REDDY'S LABS - ON JUNE 30, SUBJECT EXPERT COMMITTEE DELIBERATED ON SUBMISSION FOR MARKETING AUTHORISATION OF SPUTNIK LIGHT IN INDIA FROM CO.DR REDDY'S LABS - PRESENTED INTERIM SAFETY & EFFICACY DATA FROM PHASE I/II CLINICAL TRIAL OF SPUTNIK LIGHT IN RUSSIA.DR REDDY'S LABS - SEC RECOMMENDED THAT CO SHOULD SUBMIT SAFETY, IMMUNOGENICITY & EFFICACY DATA FROM PHASE III TRIAL OF SPUTNIK LIGHT IN RUSSIA TO SEC.DR REDDY'S LABS - PRESENTED CLINICAL TRIAL PROTOCOL FOR A PHASE III TRIAL OF SPUTNIK LIGHT IN INDIA.DR REDDY'S LABS - SEC OBSERVED INADEQUATE DATA & JUSTIFICATION IN CONDUCTING A SEPARATE TRIAL FOR SPUTNIK LIGHT.

Dr Reddy's Laboratories Announces Commercial Launch Of 2-Deoxy-D-Glucose

June 28 (Reuters) - Dr Reddy's Laboratories Ltd <REDY.NS>::ANNOUNCES COMMERCIAL LAUNCH OF 2-DEOXY-D-GLUCOSE.WILL SUPPLY TO MAJOR GOVERNMENT AS WELL AS PRIVATE HOSPITALS ACROSS INDIA.INITIALLY WILL MAKE DRUG AVAILABLE IN HOSPITALS ACROSS METROS & TIER 1 CITIES.

Dr Reddy's Announces Launch Of Icosapent Ethyl Capsules, 1 gram In U.S. Market

June 22 (Reuters) - Dr Reddy's Laboratories Ltd <REDY.NS>::ANNOUNCES LAUNCH OF ICOSAPENT ETHYL CAPSULES, 1 GRAM IN U.S. MARKET.

Rockwell Announces Collaboration With Dr. Reddy's For Sputnik V Vaccine Roll Out In India

June 9 (Reuters) - ROCKWELL INDUSTRIES::ROCKWELL INDUSTRIES ANNOUNCES COLLABORATION WITH DR. REDDY'S FOR SPUTNIK V VACCINE ROLL OUT IN INDIA - STATEMENT.ROCKWELL INDUSTRIES TO PROVIDE COVID-19 VACCINE FREEZERS TO ENABLE STORAGE OF SPUTNIK V VACCINE ACROSS INDIA - STATEMENT.Further company coverage: REDY.NS. ((Reuters.Briefs@thomsonreuters.com;)).

India's Dr.Reddy's Laboratories March-Quarter Consol Net Profit Falls

May 14 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::MARCH-QUARTER CONSOL NET PROFIT 5.54 BILLION RUPEES VERSUS PROFIT 7.64 BILLION RUPEES YEAR AGO.CONSENSUS FORECAST FOR MARCH-QUARTER CONSOL PROFIT WAS 6.48 BILLION RUPEES -- REFINITIV DATA.MARCH-QUARTER CONSOL REVENUE 47.28 BILLION RUPEES VERSUS 44.32 BILLION RUPEES YEAR AGO.RECOMMENDED A FINAL DIVIDEND OF 25 RUPEES PER SHARE.

Merck Announces Voluntary Licensing Agreements With Five Indian Generics Manufacturers To Accelerate And Expand Global Access To Molnupiravir, An Investigational Oral Therapeutic For Treatment O

April 27 (Reuters) - Merck & Co Inc <MRK.N>::MERCK ANNOUNCES VOLUNTARY LICENSING AGREEMENTS WITH FIVE INDIAN GENERICS MANUFACTURERS TO ACCELERATE AND EXPAND GLOBAL ACCESS TO MOLNUPIRAVIR, AN INVESTIGATIONAL ORAL THERAPEUTIC FOR TREATMENT OF COVID-19.MERCK & CO INC - MERCK WILL ALSO DONATE MORE THAN $5 MILLION IN SUPPLIES AND EQUIPMENT TO AID RELIEF EFFORTS IN INDIA.MERCK & CO INC - MERCK IS DEVELOPING MOLNUPIRAVIR IN COLLABORATION WITH RIDGEBACK BIOTHERAPEUTICS..MERCK & CO INC - MERCK IS ALSO IN DISCUSSIONS WITH MEDICINES PATENT POOL TO EXPLORE POTENTIAL FOR ADDITIONAL LICENSES.MERCK & CO INC - AGREEMENTS SIGNED WITH HETERO LABS LIMITED AND SUN PHARMACEUTICAL INDUSTRIES LTD.MERCK & CO INC - AGREEMENTS HAVE BEEN SIGNED WITH CIPLA LIMITED, DR. REDDY'S LABORATORIES LIMITED, EMCURE PHARMACEUTICALS LIMITED.MERCK & CO INC - MERCK WILL PROVIDE LICENSES TO THE FIVE MANUFACTURERS TO SUPPLY MOLNUPIRAVIR TO INDIA AND MORE THAN 100 LMICS..

Dr. Reddy's Exec Says Sputnik V Vaccine To Be Made Available In India This Qtr

April 14 (Reuters) - Dr. Reddy's Laboratories Exec <REDY.NS>::SPUTNIK V VACCINE WILL BE MADE AVAILABLE IN INDIA THIS QUARTER.IN TALKS WITH INDIAN GOVERNMENT FOR SPUTNIK VACCINE PRICES.250 MILLION SPUTNIK VACCINE UNITS TO COME TO INDIA.60% TO 70% SPUTNIK V VACCINE'S GLOBAL VOLUMES WILL BE MADE IN INDIA.HAVE LINED UP COLD STORAGE UNITS TO ENSURE DELIVERY OF SPUTNIK ACROSS INDIA.DON'T EXPECT TO SEEK ANY FUNDING FROM INDIAN GOVERNMENT FOR SPUTNIK VACCINE.WORKING WITH INDIAN GOVERNMENT ON SPUTNIK VACCINE SUPPLIES.EXPECT THAT BY NEXT QUARTER CAPACITY FOR SPUTNIK VACCINES WILL BE 'RAMPED UP SIGNIFICANTLY' FOR INDIA.SHOULD BE ABLE TO UPDATE ON THE PRICE OF THE VACCINE IN INDIA IN THE NEXT FEW WEEKS.WILL ENSURE SPUTNIK VACCINE MEETS SAME QUALITY, SAFETY STANDARDS IRRESPECTIVE OF WHERE IT IS MANUFACTURED.Further company coverage: REDY.NS. ((Reuters.Briefs@thomsonreuters.com;)).

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up